Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer
This study will help researchers test the safety of hypofractionated dose of radiotherapy (HySBst) at different dose levels before or after chemo-radiation for Non Small Cell Lung Cancer.
Checked against the public recordLast updated May 30, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- West Virginia University
- Interventions being studied
- Radiation: Hypofractionated Stereotactic Boost; Drug: Carboplatin; Drug: Paclitaxel; Radiation: Image-guided IMRT
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Stage II - III Non Small Cell Lung Cancer Exclusion Criteria: * Primary tumor directly invading into any mediastinal structures, such as the heart, major blood vessels, esophagus, trachea, and the proximal bronchial tree. * Prior chemotherapy for NSCLC * Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields. * Severe, active co-morbidity * Pregnancy or women of childbearing potential * Any history of allergic reaction to paclitaxel or other taxanes, or to carboplatin * Uncontrolled neuropathy ≥ grade 2.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- West Virginia University Hospitals Mary Babb Randolph Cancer CenterMorgantown, West Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 30, 2018. Always confirm current availability with the study team.